erectile%20dysfunction
ERECTILE DYSFUNCTION

Erectile dysfunction is the inability to attain and maintain an erection enough to have satisfactory sexual performance for ≥3 months.

It is when the patient complains of partial erection that could not attain vaginal penetration.

Complete loss of penile rigidity is uncommon.

Initial penile erections can penetrate but early detumescence occurs without ejaculation.

  1. Andersson KE. Pharmacology of erectile function and dysfunction. Urol Clin North Am. 2001 May;28(2):233-247. PMID: 11402577
  2. American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of male sexual dysfunction: a couple's problem -2003 update. Endocr Pract. 2003 Jan;9(1):77-95. PMID: 12917096
  3. Becher E. Topical alprostadil cream for the treatment of erectile dysfunction. Expert Opin Pharmacother. 2004 Mar;5(3):623-632. PMID: 15013930
  4. Ernst E, Pittler MH. Yohimbine for erectile dysfunction: a systematic review and meta-analysis for randomized clinical trials [abstract]. J Urol. 1998 Feb;159(2):433-436. PMID: 9649257
  5. Lue TF. Erectile dysfunction. N Engl J Med. 2000 Jun;342(24):1802-1813. PMID: 10853004
  6. Montorsi F, Salonia A, Deho F, et al. Pharmacological management of erectile dysfunction. BJU Int. 2003 Mar;91(5):446-454. PMID: 12603396
  7. Morales A, Heaton JP. Hormonal erectile dysfunction. Evaluation and management. Urol Clin North Am. 2001 May;28(2):279-288. PMID: 11402581
  8. Morgentaler A. Male impotence. Lancet. 1999 Nov;354(9191):1713-1718. PMID: 10568586
  9. MedWormhttp://www.medworm.com/rss/index.php/Endocrinology/15/http://www.medworm.com/rss/medicalfeeds/specialities/Endocrinology.xml
  10. Malaysia Urological Association and MEDACT. Clinical Practice Guide in Erectile Dysfunction. www.acadmed.org.my/view_file.cfm?fileid=211. Aug 2000
  11. American Urological Association Education and Research, Inc. Management of erectile dysfunction [chapter 1 w/ appendix: diagnosis and treatment guideline]. http://www.auanet.org/education/guidelines/erectile-dysfunction.cfm. 2005
  12. British Society for Sexual Medicine. Guidelines on the management of erectile dysfunction. http://www.bssm.org.uk/downloads/BSSM_ED_Management_Guidelines_2009.pdf. 2009
  13. Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997 Jun;49(6):822-830. PMID: 9187685
  14. Wespes E, Eardley I, Giuliano F, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. European Association of Urology (EAU). http://www.uroweb.org/gls/pdf/14_Male%20Sexual%20Dysfunction_LR.pdf. 2013 Mar. Accessed 11 Feb 2014.
  15. Hatzimouratidis K, Eardley I, Giuliano F, et al. European Association of Urology guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. 2015 Mar:1-53.
  16. Bella A, Lee J, Carrier S, et al. 2015 Canadian Urological Association practice guidelines for erectile dysfunction. Can Urol Assoc J. 2015 Jan;9(1-2):23-29. doi: 10.5489/cuaj.2699. PMID: 25737750
  17. Alhathal N, Elshal AM, Carrier S. Synergetic effect of testosterone and phophodiesterase-5 inhibitors in hypogonadal men with erectile dysfunction: a systematic review. Can Urol Assoc J. 2012 Aug;6(4):269-274. doi: 10.5489/cuaj.11291. PMID: 23093538
  18. Duggin M. Erectile Dysfunction. In: Kellerman R D, Bope E T. Conn's Current Therapy 2018. Philadelphia, PA: Saunders, an imprint of Elsevier, Inc.; 2018. http://dx.doi.org/10.1016/B978-0-323-52769-9.00251-8. Accessed 06 Feb 2018:1068-1070.
  19. Wincze J P. Erectile Dysfunction. In: Ferri F. Ferri's Clinical Advisor 2018. Philadelphia, PA: Elsevier, Inc; 2018. 466-467. :466-467.
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.